Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Geron ( (GERN) ) has issued an announcement.
On March 25, 2026, Geron Corporation’s board elected industry veterans Patricia S. Andrews and Constantine Chinoporos as Class III directors, with terms running until the 2026 annual shareholders’ meeting, and appointed Andrews to the audit committee. Both will receive standard non-employee director compensation and enter into Geron’s customary indemnification agreements, underscoring the company’s efforts to strengthen governance and protect its board members.
Andrews brings extensive oncology and commercial leadership experience from roles at Sumitomo Pharma Oncology, Incyte and Pfizer, as well as board positions at Glenmark Pharmaceuticals, Ichnos Glenmark Innovation and Oncolytics Biotech, while Chinoporos adds a track record in business development and corporate strategy from posts at Applied Therapeutics, Albireo, Boston Pharmaceuticals, Sanofi, Genzyme and Eli Lilly. Their appointments signal Geron’s intent to bolster strategic, financial and deal-making expertise at the board level, which could influence the company’s future corporate development and industry positioning.
The most recent analyst rating on (GERN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.
Spark’s Take on GERN Stock
According to Spark, TipRanks’ AI Analyst, GERN is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong gross margins, and no debt) but held back by substantial ongoing cash burn and continued losses. Technicals are supportive with price above major moving averages, while valuation is constrained by negative earnings and no dividend. Earnings call commentary adds a moderate positive tilt via 2026 growth guidance and expense reduction targets, tempered by cash decline and gross-to-net/reimbursement risks.
To see Spark’s full report on GERN stock, click here.
More about Geron
Geron Corporation operates in the biopharmaceutical sector, focusing on the development and commercialization of therapies, with a particular emphasis on oncology and serious diseases. The company is governed by a board that includes non-employee directors who receive standard cash and equity compensation and are covered by indemnification agreements for their board service.
Average Trading Volume: 15,509,704
Technical Sentiment Signal: Sell
Current Market Cap: $1.01B
Learn more about GERN stock on TipRanks’ Stock Analysis page.